Skip to content

MAZE MAZE Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
$993K

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: MAZE’s 10-K, filed March 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's payments of stock issuance costs?
MAZE (MAZE) reported payments of stock issuance costs of $788.5K in Q4 2024.
What does payments of stock issuance costs mean?
Includes direct costs such as underwriting fees, legal expenses, and accounting fees incurred to raise capital through equity offerings. Monitoring these costs is essential for evaluating the efficiency of the company's capital-raising activities.